These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 36940725)

  • 1. Induction of the alternative lengthening of telomeres pathway by trapping of proteins on DNA.
    Rose AM; Goncalves T; Cunniffe S; Geiller HEB; Kent T; Shepherd S; Ratnaweera M; O'Sullivan RJ; Gibbons RJ; Clynes D
    Nucleic Acids Res; 2023 Jul; 51(13):6509-6527. PubMed ID: 36940725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
    Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
    Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
    Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
    PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
    Li F; Deng Z; Zhang L; Wu C; Jin Y; Hwang I; Vladimirova O; Xu L; Yang L; Lu B; Dheekollu J; Li JY; Feng H; Hu J; Vakoc CR; Ying H; Paik J; Lieberman PM; Zheng H
    EMBO J; 2019 Oct; 38(19):e96659. PubMed ID: 31454099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATRX modulates the escape from a telomere crisis.
    Geiller HEB; Harvey A; Jones RE; Grimstead JW; Cleal K; Hendrickson EA; Baird DM
    PLoS Genet; 2022 Nov; 18(11):e1010485. PubMed ID: 36350851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-genetic switch triggers alternative telomere lengthening and cellular immortalization in ATRX deficient cells.
    Turkalo TK; Maffia A; Schabort JJ; Regalado SG; Bhakta M; Blanchette M; Spierings DCJ; Lansdorp PM; Hockemeyer D
    Nat Commun; 2023 Feb; 14(1):939. PubMed ID: 36805596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening.
    Kim J; Sun C; Tran AD; Chin PJ; Ruiz PD; Wang K; Gibbons RJ; Gamble MJ; Liu Y; Oberdoerffer P
    Nat Struct Mol Biol; 2019 Mar; 26(3):213-219. PubMed ID: 30833786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
    Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
    PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathway choice in the alternative telomere lengthening in neoplasia is dictated by replication fork processing mediated by EXD2's nuclease activity.
    Broderick R; Cherdyntseva V; Nieminuszczy J; Dragona E; Kyriakaki M; Evmorfopoulou T; Gagos S; Niedzwiedz W
    Nat Commun; 2023 Apr; 14(1):2428. PubMed ID: 37105990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats.
    Nguyen DT; Voon HPJ; Xella B; Scott C; Clynes D; Babbs C; Ayyub H; Kerry J; Sharpe JA; Sloane-Stanley JA; Butler S; Fisher CA; Gray NE; Jenuwein T; Higgs DR; Gibbons RJ
    EMBO Rep; 2017 Jun; 18(6):914-928. PubMed ID: 28487353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
    Mori JO; Keegan J; Flynn RL; Heaphy CM
    J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
    Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
    Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
    Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
    Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
    Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
    Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.